Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
General11 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News15 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
General17 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay
-
Noosa News23 hours agoCat-Sitting Leads to Chaos for Austin Butler in the Trailer for Darren Aronofsky’s New Crime-Thriller ‘Caught Stealing’